SCHEMBL623312

SCHEMBL623312

COC(=O)c1cc(Oc2cnc(N)s2)ccc1C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GCK P35557 2/20 0.38
GAA P10253 6/20 0.37
KDM4E B2RXH2 4/20 0.37
ALDH1A1 P00352 4/20 0.37
PKM P14618 2/20 0.37
KMT2A Q03164 2/20 0.37
CYP3A4 P08684 2/20 0.37
CYP1A2 P05177 2/20 0.37
CYP2C19 P33261 2/20 0.37
GLA P06280 2/20 0.37
MAPT P10636 4/20 0.36
LMNA P02545 2/20 0.36
KDR P35968 1/20 0.36
HPGD P15428 2/20 0.36
MEN1 O00255 1/20 0.36
P2RX3 P56373 1/20 0.36
CISD2 Q8N5K1 1/20 0.36
MAPK1 P28482 1/20 0.36
KCNH2 Q12809 1/20 0.35
DRD1 P21728 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11972293 0.90 GAA (0.40) GCKGAAKDM4EALDH1A1PKM
SCHEMBL9071240 0.90 ALDH1A1 (0.39) GAAKDM4EALDH1A1PKMKMT2A
SCHEMBL11971998 0.86 ALDH1A1 (0.43) GCKGAAKDM4EALDH1A1PKM
SCHEMBL11972318 0.86 ILK (0.38) GCKGAAKDM4EALDH1A1PKM
SCHEMBL11972292 0.85 TP53 (0.44) GCKGAAKDM4EALDH1A1PKM
SCHEMBL185090 0.84 ILK (0.38) GCKGAAKDM4EALDH1A1PKM
SCHEMBL11971906 0.84 ABL1 (0.42) GCKGAAKDM4EALDH1A1PKM
SCHEMBL184607 0.80 MAPT (0.47) KDM4EALDH1A1CYP3A4GLAMAPT
SCHEMBL623541 0.80 GCK (0.37) GCKKDM4EKMT2ADRD1TSHR
SCHEMBL11972175 0.79 ALDH1A1 (0.41) ALDH1A1KDRP2RX3MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9340506-B2 Acetamide derivatives as glucokinase activators, their process and medicinal applications ADVINUS THERAPEUTICS LIMITED (IN) 2016-05-17 US disclosed
US-20120214735-A1 ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATIONS ADVINUS THERAPEUTICS LIMITED (IN) 2012-08-23 US disclosed
WO-2012020357-A1 ACETAMIDE COMPOUNDS, THEIR PROCESS AND PHARMACEUTICAL APPLICATION ADVINUS THERAPEUTICS LTD. (IN) 2012-02-16 WO disclosed
WO-2012020357-A1 ACETAMIDE COMPOUNDS, THEIR PROCESS AND PHARMACEUTICAL APPLICATION ADVINUS THERAPEUTICS LTD. (IN) 2012-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120214735-A1 ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATIONS GCK, GCKR, ALDOA GCK 1/4885GAA 67/4885KDM4E 3894/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.